China has made significant progress in stem cell therapy for diabetes: several patients with type 1 diabetes who received stem cell treatment have successfully discontinued insulin injections, and some have remained medication-free for several years. This achievement brings new hope to diabetes patients worldwide.
Treatment principle and clinical progress
The core idea of stem cell therapy is to restore damaged islet function by transplanting stem cells capable of secreting insulin. Multiple medical and research institutions in China are conducting related clinical trials. Preliminary data show that some patients experienced notable recovery of islet function and stabilization of blood glucose levels after treatment.
Compared with daily multiple insulin injections, stem cell therapy has the potential to fundamentally reduce the treatment burden on patients and improve long-term complication risks. However, the technology is still in the clinical research stage, and rigorous patient screening and long-term safety evaluation must proceed with caution.
Suitable patients and precautions
Currently, clinical trials mainly target patients with type 1 diabetes who have poor blood glucose control and severely impaired islet function. Patients should obtain project information through regulated medical institutions and be wary of exaggerated claims from unregulated providers.
MedBridge support services
MedBridge can help international patients learn about the progress of stem cell clinical programs at medical institutions in Shanghai, providing hospital consultation, program evaluation and arrangements for treatment in Shanghai, so patients can make rational decisions based on authoritative information.